Status:
COMPLETED
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
Lead Sponsor:
University of Michigan Rogel Cancer Center
Collaborating Sponsors:
Damon Runyon Cancer Research Foundation
Conditions:
Breast Cancer
Pain
Eligibility:
FEMALE
21+ years
Brief Summary
Postmenopausal women who have hormone receptor positive breast cancer are typically treated with aromatase inhibitor medications, which substantially decrease the amount of estrogen produced by their ...
Eligibility Criteria
Inclusion
- Female gender
- Postmenopausal, age 21 or greater
- Stage 0-III estrogen receptor and/or progesterone receptor positive breast cancer who will be receiving a standard dose of letrozole, anastrozole, or exemestane
- Performance status 0-2
- Willing to sign the consent form
Exclusion
- Average pain \>=8/10 over the past 24 hours
- Peripheral sensory neuropathy grade 2 or higher
- Personal history of schizophrenia, or suicidal ideation or attempt within the past 2 years
- Thumbnail abnormalities on either hand that are likely to alter pain perception during testing
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01814397
Start Date
July 1 2009
End Date
February 1 2013
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109